deficiency is hypocalcemia due to hypoparathyroidism, but there are many uncertainties about the pathophysiology and pathogenic mechanism of hypoparathyroidism caused by Mg deficiency.
Impaired secretion of parathyroid hormone (PTH) has been thought to be a major mechanismof hypocalcemia in Mg deficiency. In many but not all hypomagnesemic patients, the serum PTHlevels are either low or within the normal range despite the presence of hypocalcemia. These findings along with the fact that serum PTH levels increase sharply after Mg supplementation indicate that PTH secretion is impaired in these patients. The most important regulator of PTHsecretion is serum ionized calcium (Ca); a Ca-sensing receptor has been cloned in parathyroid cells (1) . Binding ofCa with this receptor causes an increase in inositol triphosphate production and an elevation in the intracellular Ca concentration ( 1 ) , and is thought to cause a reduction in PTHsecretion. Mgappears to compete with Ca for this receptor, with an affinity two-to three-fold less than that for Ca, causing a rise in the intracellular Ca concentration (2) . In addition, an in vitro study using rat parathyroid cells demonstrated that deletion of Mgfrom the mediumreduces PTH release at a constant Ca concentration (3) . Thus, Mgacts as a Ca agonist at very high concentrations (4) but may serve as an antagonist at lower concentrations. Based upon these observations, the reduced PTHsecretion in hypomagnesemiacan be explained by a reduction in the competitive inhibition by Mgof Ca binding to its receptor. Such an alteration in Ca binding to its receptor enables parathyroid cells to respond to serum Ca with higher sensitivity and causes a reduction in PTHsecretion at lower serum Ca concentrations. However, the possibility remains that Mgmayalso affect PTHsecretion at other steps in parathyroid cells. Reduced responsiveness to PTHhas also been reported in some patients with hypomagnesemia. One of the postulated sites that causes the disturbance in responsiveness to PTHis adenylate cyclase. There are reports of patients with hypomagnesemia with a reduced urinary cyclic AMPresponse to PTH (5). Because Mgis required for the catalytic activity of the enzyme, reduction in the intracellular Mgconcentration can suppress the enzymeactivity. However,manypatients with Mg deficiency respond to PTHnormally in terms of urinary cyclic AMPexcretion, as in the case reported by Mihara et al (6) in this issue of the Journal. In addition, in some of the patients with a blunted response to PTHin urinary cyclic AMPexcretion, the increase in plasma cyclic AMPin response to glucagon was normal (5). Although these discrepancies can be explained by a difference in the concentration of Mgrequired for the catalytic activity of adenylate cyclase in different tissues, little data is available to support such a possibility. In a study using dogs, responsiveness to PTHwas found to decline progressively with increasing degree of Mgdeficiency (7). Rude et al (5) reported that most of the cases with a reduced urinary cyclic AMP response to PTHhave severe hypomagnesemiaof 0.6 mg/dl or below; they suggested that only those patients with severe Mg deficiency may develop a blunted renal cyclic AMPresponse to PTH.However,there are manypatients with severe hypomagnesemia with normal cyclic AMPresponse to PTH. In the report of Mihara et al (6), they suggested that in their patient, the steps distal to cyclic AMPproduction in response to PTH may be impaired by Mg deficiency. However, responsiveness to PTHby the Ellsworth-Howard test was normal in terms of urinary cyclic AMPand phosphate excretion. Because the test was performed 12 days after admission whenserum Mg rose to 1.0 mg/dl and serum phosphate as well as TmP/GFR were normalized, such a possibility could have been better delineated if PTHinfusion had been performed prior to the treatment when serum Mgwas 0.6 mg/dl and serum phosphate and TmP/GFR were elevated. The examination of the renal responsiveness to dibutyryl cyclic AMPinfusion may also provide some insight to the question of whether Mgdeficiency can cause resistance to PTHat a step distal to cyclic AMP production.
Serum 1 ,25-dihydroxyvitamin D is also very low in patients with Mg deficiency. Although serum PTHand nephrogenous cyclic AMPincrease rapidly in response to Mgsupplementation, 1 , 9) . In addition, serum osteocalcin, a marker for bone formation, is markedly low in Mgdeficiency and increases long after serum PTH is normalized (10). Furthermore, serum Ca increases with a similar time course to that seen in serum osteocalcin (10). These observations suggest that the reduction in responsiveness to PTH by Mg deficiency cannot be fully explained by a reduction in the catalytic activity of adenylate cyclase. Mgis required for many aspects of cellular activity, and the difference in clinical features of Mgdeficiency may be due to a variation in the extent and/or the degree of impairmentin these multiple steps of cellular functions. Although much has to be clarified to 
